Skip Navigation


JAC Advance Access originally published online on July 15, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/294    most recent
dkg363v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Frean, J.
Right arrow Articles by Bukofzer, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frean, J.
Right arrow Articles by Bukofzer, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 294-296
© 2003 The British Society for Antimicrobial Chemotherapy

Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents

John Frean1, Keith P. Klugman2,3,*, Lorraine Arntzen1 and Stanley Bukofzer4

1 National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg; 2 MRC/University of the Witwatersrand/NHLS Respiratory and Meningeal Pathogens Research Unit, Johannesburg, South Africa; 3 Department of International Health, Emory University, Atlanta, GA; 4 Abbott Laboratories, Abbott Park, Chicago, IL, USA

Received 3 April 2003; returned 28 April 2003; revised 4 June 2003; accepted 10 June 2003

Objectives: To determine the susceptibility of southern African strains of Yersinia pestis to novel as well as conventional antimicrobial agents.

Materials and methods: The MICs of 28 strains of Yersinia pestis from a southern African plague focus were determined by agar dilution.

Results: The most active agents were cefditoren and the fluoroquinolones, both conventional and novel. The in vitro activity of macrolides was poor against this member of the Enterobacteriaceae.

Conclusion: Further investigation of the novel quinolones olamufloxacin (HSR 903) and ABT 492 in animal models of plague would seem to be justified.

Keywords: plague, antibiotics, fluoroquinolones, macrolides, ketolides

* Corresponding author. Tel: +1-404-712-9001; Fax: +1-404-727-4590; E-mail: kklugma{at}sph.emory.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MicrobiologyHome page
C. L. Airhart, H. N. Rohde, G. A. Bohach, C. J. Hovde, C. F. Deobald, S. S. Lee, and S. A. Minnich
Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague
Microbiology, July 1, 2008; 154(7): 2131 - 2138.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
A. P. Anisimov and K. K. Amoako
Treatment of plague: promising alternatives to antibiotics.
J. Med. Microbiol., November 1, 2006; 55(Pt 11): 1461 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Galimand, E. Carniel, and P. Courvalin
Resistance of Yersinia pestis to Antimicrobial Agents.
Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3233 - 3236.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.